Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK4 | P11802 | 20/20 | 0.66 |
| ▸ | CCND1 | P24385 | 20/20 | 0.66 |
| ▸ | CCND3 | P30281 | 20/20 | 0.66 |
| ▸ | CDK6 | Q00534 | 20/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30888977 | 1.00 | CDK4 (0.66) | CDK4CCND1CCND3CDK6 | |
| SCHEMBL29268584 | 0.91 | CDK4 (0.56) | CDK4CCND1CCND3CDK6 | |
| SCHEMBL21522659 | 0.86 | CDK4 (0.52) | CDK4CCND1CCND3CDK6 | |
| SCHEMBL21522851 | 0.84 | CDK4 (0.77) | CDK4CCND1CCND3CDK6 | |
| SCHEMBL21522731 | 0.80 | CDK4 (1.00) | CDK4CCND1CCND3CDK6 | |
| SCHEMBL30888969 | 0.80 | CDK4 (0.49) | CDK4CCND1CCND3CDK6 | |
| SCHEMBL21522786 | 0.80 | CDK4 (0.49) | CDK4CCND1CCND3CDK6 | |
| SCHEMBL30889003 | 0.76 | CDK4 (0.45) | CDK4CCND1CCND3CDK6 | |
| SCHEMBL29268589 | 0.76 | CDK4 (0.45) | CDK4CCND1CCND3CDK6 | |
| SCHEMBL19836706 | 0.75 | CDK4 (0.54) | CDK4CCND1CCND3CDK6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12378232-B2 | Cyclin dependent kinase inhibitors | PFIZER INC. (US) | 2025-08-05 | — | — | US | disclosed |
| EP-3784664-B1 | 2-AMINO-PYRIDINE OR 2-AMINO-PYRIMIDINE DERIVATIVES AS CYCLIN DEPENDENT KINASE INHIBITORS | PFIZER (US) | 2025-02-19 | — | — | EP | disclosed |
| CN-118286225-A | 2-Amino-pyridine or 2-amino-pyrimidine derivatives as cyclin dependent kinase inhibitors | 辉瑞公司 | 2024-07-05 | — | — | CN | disclosed |
| CN-112313219-B | 2-Amino-pyridine or 2-amino-pyrimidine derivatives as cyclin dependent kinase inhibitors | 辉瑞公司 | 2024-04-26 | — | — | CN | disclosed |
| US-20220089580-A1 | CYCLIN DEPENDENT KINASE INHIBITORS | PFIZER INC. (US) | 2022-03-24 | — | — | US | disclosed |
| US-20220089580-A1 | CYCLIN DEPENDENT KINASE INHIBITORS | PFIZER INC. (US) | 2022-03-24 | — | — | US | disclosed |
| US-11220494-B2 | Cyclin dependent kinase inhibitors | PFIZER INC. (US) | 2022-01-11 | — | — | US | disclosed |
| US-11220494-B2 | Cyclin dependent kinase inhibitors | PFIZER INC. (US) | 2022-01-11 | — | — | US | disclosed |
| EP-3784664-A1 | 2-AMINO-PYRIDINE OR 2-AMINO-PYRIMIDINE DERIVATIVES AS CYCLIN DEPENDENT KINASE INHIBITORS | Pfizer Inc. (US) | 2021-03-03 | — | — | EP | disclosed |
| US-20200354350-A1 | CYCLIN DEPENDENT KINASE INHIBITORS | PFIZER INC. (US) | 2020-11-12 | — | — | US | disclosed |
| US-20200354350-A1 | CYCLIN DEPENDENT KINASE INHIBITORS | PFIZER INC. (US) | 2020-11-12 | — | — | US | disclosed |
| US-10766884-B2 | Cyclin dependent kinase inhibitors | PFIZER INC. (US) | 2020-09-08 | — | — | US | disclosed |
| US-10766884-B2 | Cyclin dependent kinase inhibitors | PFIZER INC. (US) | 2020-09-08 | — | — | US | disclosed |
| US-20190330196-A1 | CYCLIN DEPENDENT KINASE INHIBITORS | PFIZER INC. (US) | 2019-10-31 | — | — | US | disclosed |
| US-20190330196-A1 | CYCLIN DEPENDENT KINASE INHIBITORS | PFIZER INC. (US) | 2019-10-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10766884-B2 | Cyclin dependent kinase inhibitors | CCNY, CCNI, CCNK | CDK4 27/4885CCND1 13/4885CCND3 10/4885 |
| US-20200354350-A1 | CYCLIN DEPENDENT KINASE INHIBITORS | CCNY, CCNI, CCNK | CDK4 27/4885CCND1 13/4885CCND3 10/4885 |
| US-12378232-B2 | Cyclin dependent kinase inhibitors | CCNY, CCNI, CCNK | CDK4 27/4885CCND1 13/4885CCND3 10/4885 |
| US-20190330196-A1 | CYCLIN DEPENDENT KINASE INHIBITORS | CCNY, CCNI, CCNK | CDK4 27/4885CCND1 13/4885CCND3 10/4885 |
| US-11220494-B2 | Cyclin dependent kinase inhibitors | CCNY, CCNI, CCNK | CDK4 27/4885CCND1 13/4885CCND3 10/4885 |
| US-20220089580-A1 | CYCLIN DEPENDENT KINASE INHIBITORS | CCNY, CCNI, CCNK | CDK4 27/4885CCND1 13/4885CCND3 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.